Brief: Aerovate Therapeutics And Jade Biosciences Announce Merger Agreement
31/10/2024 11:07
Oct 31 (Reuters) - Aerovate Therapeutics Inc AVTE.O :
* AEROVATE THERAPEUTICS AND JADE BIOSCIENCES ANNOUNCE MERGER
AGREEMENT
* AEROVATE THERAPEUTICS INC - JADE SECURES $300 MILLION IN
PRIVATE
INVESTMENT
* AEROVATE THERAPEUTICS INC - STOCKHOLDERS TO OWN 1.6% OF
COMBINED
COMPANY
* AEROVATE THERAPEUTICS INC - TOM FROHLICH TO LEAD COMBINED
COMPANY AS CEO
* AEROVATE THERAPEUTICS INC - TO DECLARE $65 MILLION CASH
DIVIDEND
TO STOCKHOLDERS
Source text: ID:nGNX3X49Mt
Further company coverage: AVTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million